• Silymarin: From Chemical Identity to Assay Insight

  2026-09-01

  Silymarin is a chemically complex milk thistle extract whose flavonolignan composition directly shapes experimental interpretation. This guide connects stereochemical chemistry with assay design across oxidative stress, cancer, metabolic, and antiviral research.

• Thiazovivin (A5506): Practical ROCK Inhibitor Guide

  2026-09-01

  Thiazovivin (SKU A5506) is a ROCK inhibitor used to address poor cell recovery after trypsinization and to support fibroblast reprogramming workflows for induced pluripotent stem cell generation. This guide covers material handling, controls, and optimization boundaries; it is intended for stem cell research only and not for diagnostic, therapeutic, or medical use.

• In Vitro Drug Responses: Beyond Relative Viability

  2026-08-31

  Hannah Schwartz’s dissertation shows that relative viability and fractional viability capture different dimensions of anticancer drug response: growth inhibition and cell killing. Its central practical contribution is a more discriminating in vitro framework that considers response magnitude, composition, and timing rather than treating a single viability value as a complete pharmacologic phenotype.

• Heart–Brain Axis Dysregulation in PTSD Mice

  2026-08-31

  A 2026 European Journal of Pharmacology study identifies a vagus-mediated pathway linking sympathetically driven cardiac overactivation to insular cortex hyperactivity and PTSD-like behavior in mice. Its use of isoproterenol, vagotomy, electrophysiology, and propranolol provides a mechanistic framework for studying β-adrenergic receptor signaling pathway effects across cardiovascular and neurobehavioral systems.

• Anlotinib Hydrochloride: From Angiogenesis to Translation

  2026-08-30

  Anlotinib hydrochloride offers translational researchers a mechanistically coherent way to connect VEGFR2, PDGFRβ, FGFR1, endothelial phenotypes, ERK signaling, and tumor-response hypotheses in cancer research.

• Ibrutinib (PCI-32765) BTK Inhibitor Workflow

  2026-08-29

  Build cleaner B-cell experiments with Ibrutinib (PCI-32765), from solvent handling and BCR stimulation to washout designs that exploit irreversible BTK inhibition. A reference study in amyloid models provides a useful framework for factorial controls and orthogonal phenotyping, while its non-B-cell context defines important translational limits.

• FAK Inhibitor 14: Mapping FAK-Driven Tumor Cell State

  2026-08-28

  FAK Inhibitor 14 enables mechanistic analysis of how focal adhesion kinase connects persistent cholesterol stress with EMT, adhesion, and motility. This article presents a causal assay framework that distinguishes pathway-specific biology from nonspecific toxicity in cancer biology research.

• Reversine: Aurora Kinase Inhibitor Guide

  2026-08-28

  Reversine is an Aurora kinase inhibitor used to interrogate mitotic control, cancer cell proliferation inhibition, and apoptosis induction in cancer cells. Its reported Aurora A, B, and C IC50 values are 150 nM, 500 nM, and 400 nM, respectively, while its water-insoluble formulation requires solvent-matched experimental handling.

• SB203580 Workflows for p38 MAPK Research

  2026-08-27

  Use SB203580 as a pathway-perturbation tool to separate p38 MAPK signaling from upstream activation, downstream transcription, and regenerative function. This practical guide adapts findings from diabetic bladder dysfunction research into cell-based workflows, controls, dosing logic, and troubleshooting strategies.

• GSK621: AMPK Agonist for AML Metabolism

  2026-08-27

  GSK621 enables controlled AMPK pathway activation across acute myeloid leukemia, metabolic, and tumor-macrophage assays. This guide combines practical handling, phospho-signaling workflows, apoptosis and autophagy readouts, and a mechanistic bridge to 25-hydroxycholesterol biology.

• Transmembrane Protein Degradation by ERAD

  2026-08-26

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a small-molecule strategy that redirects the endoplasmic reticulum-associated degradation pathway toward transmembrane proteins. By using desonide to engage the ER E3 ligase SYVN1, the study achieves potent PD-L1 degradation and demonstrates a broader route for targeted protein degradation beyond lysosome-dependent systems.

• Quercetin and Ferroptosis in Wilson’s Disease

  2026-08-26

  A 2026 Phytomedicine study shows that Quercetin reduces hepatic injury in Wilson’s disease models by suppressing ferroptosis through the ACSL4/LPCAT3/ALOX15 axis. Its integrated use of lipidomics, biochemical assays, ultrastructural analysis, and target-engagement experiments provides a mechanistic framework for studying metal-overload liver injury, while remaining preclinical.

• H-89 and Bone Anabolism: Testing the PKA–Wnt Axis

  2026-08-25

  H-89 provides a practical pharmacological entry point for testing how cAMP-dependent protein kinase activity connects Wnt signaling with O-GlcNAcylation, glycolysis, and osteoblastogenesis. This article translates recent bone biology into an experimentally disciplined strategy for pathway validation and translational decision-making.

• Hydrocortisone: From Receptor Assay to Delivery Design

  2026-08-25

  Hydrocortisone is more than a glucocorticoid hormone reference: it can connect receptor biology with controlled-delivery engineering. This article translates recent PLGA microsphere findings into practical decisions for inflammation, barrier, stress-response, and cartilage studies.

• Neuroligin 1, PKC, and Repetitive Behavior

  2026-08-24

  The reference study identifies a cell-type-specific mechanism linking Neuroligin 1 loss in striatal D2 receptor-expressing medium spiny neurons to autistic-like repetitive behavior. By integrating behavioral manipulation, neuronal activity analysis, single-nucleus RNA sequencing, and protein validation, the work implicates excessive PKC signaling and altered D2-MSN excitability as mechanistic contributors.

8084 records 1/539 page Next 12345 下5页 Last page